{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:45:57Z","timestamp":1793029557773,"version":"4.5.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115303"],"award-info":[{"award-number":["115303"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","award":["115303"],"award-info":[{"award-number":["115303"]}],"id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1003348","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T13:23:41Z","timestamp":1604064221000},"page":"e1003348","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":59,"title":["Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4263-3079","authenticated-orcid":true,"given":"Signe","family":"H\u00e4ssler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0547-008X","authenticated-orcid":true,"given":"Delphine","family":"Bachelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-6162","authenticated-orcid":true,"given":"Julianne","family":"Duhaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Szely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Gleizes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Hacein-Bey Abina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-9210","authenticated-orcid":true,"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-4225","authenticated-orcid":true,"given":"Michael","family":"Auer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-218X","authenticated-orcid":true,"given":"Jer\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Birchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Brocq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Buck-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cadiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2373-6657","authenticated-orcid":true,"given":"Manuel","family":"Comabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Derfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6257-8604","authenticated-orcid":true,"given":"Niek","family":"De Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoimh","family":"Donnellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiba","family":"Doukani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-781X","authenticated-orcid":true,"given":"Michael","family":"Guger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-4359","authenticated-orcid":true,"given":"Eva","family":"Kubala Havrdova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Ingenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul Erik","family":"Hyldgaard-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-3396","authenticated-orcid":true,"given":"Elizabeth C.","family":"Jury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-3328","authenticated-orcid":true,"given":"Michael","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Laur\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-314X","authenticated-orcid":true,"given":"Raija","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-7441","authenticated-orcid":true,"given":"Amy","family":"Loercher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1209-4417","authenticated-orcid":true,"given":"Jessica","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badreddine","family":"Mohand Oumoussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9583-8946","authenticated-orcid":true,"given":"Maria","family":"Nachury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Nytrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Ryner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sievers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sikkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-0720","authenticated-orcid":true,"given":"Martin","family":"Soubrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tourdot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-5844","authenticated-orcid":true,"given":"Caroline","family":"Trang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-9255","authenticated-orcid":true,"given":"Clemens","family":"Warnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4682-9538","authenticated-orcid":true,"given":"Sebastian","family":"Spindeldreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-2952","authenticated-orcid":true,"given":"Pierre","family":"D\u00f6nnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hickling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Hincelin Mery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2012-7522","authenticated-orcid":true,"given":"Matthieu","family":"Allez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4541-8841","authenticated-orcid":true,"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0311-9184","authenticated-orcid":true,"given":"Anna","family":"Fogdell-Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":true,"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pallardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-2810","authenticated-orcid":true,"given":"Philippe","family":"Bro\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ABIRISK consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"pmed.1003348.ref001","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-75841-1","volume-title":"Immunogenicity of Biopharmaceuticals","author":"M van de Weert","year":"2008"},{"issue":"4","key":"pmed.1003348.ref002","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides\u2014Harmonized Terminology and Tactical Recommendations.","volume":"16","author":"G Shankar","year":"2014","journal-title":"AAPS J"},{"issue":"3","key":"pmed.1003348.ref003","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the Immunogenicity of Biopharmaceuticals.","volume":"30","author":"C Pineda","year":"2016","journal-title":"BioDrugs"},{"issue":"3","key":"pmed.1003348.ref004","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/cei.12652","article-title":"Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium: Immunogenicity of biopharmaceuticals: ABIRISK recommendations","volume":"181","author":"B Rup","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"pmed.1003348.ref005","unstructured":"ABIRISK Consortium. ABIRISK: Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk [Internet]. 2018 [cited 2020 Jan 1]. Available from: https:\/\/www.imi.europa.eu\/projects-results\/project-factsheets\/abiriskref:end"},{"issue":"5","key":"pmed.1003348.ref006","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the Validation of Immunoassays Used for Detection of Host Antibodies against Biotechnology Products","volume":"48","author":"G Shankar","year":"2008","journal-title":"Journal of Pharm Biomed Anal"},{"key":"pmed.1003348.ref007","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fneur.2017.00305","article-title":"Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta","volume":"8","author":"K Ingenhoven","year":"2017","journal-title":"Front Neurol"},{"key":"pmed.1003348.ref008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.01.004","article-title":"Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta","volume":"430","author":"C Hermanrud","year":"2016","journal-title":"J Immunol Methods"},{"key":"pmed.1003348.ref009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2018.11.002","article-title":"Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study","volume":"326","author":"PEH Jensen","year":"2019","journal-title":"J Neuroimmunol"},{"key":"pmed.1003348.ref010","unstructured":"Perdry H, Dandine-Roulland C. \u201cgaston\u201d R package. April 2019. Available from: https:\/\/CRAN.R-project.org\/package=gaston"},{"key":"pmed.1003348.ref011","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/tpj.2013.18","article-title":"HIBAG\u2014HLA genotype imputation with attribute bagging","volume":"14","author":"X Zheng","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"pmed.1003348.ref012","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The Statistical Analysis of Failure Time Data: Kalbfleisch\/The Statistical","author":"JD Kalbfleisch","year":"2002"},{"issue":"7","key":"pmed.1003348.ref013","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrg2813","article-title":"New Approaches to Population Stratification in Genome-Wide Association Studies","volume":"11","author":"AL Price","year":"2010","journal-title":"Nature Reviews. Genetics"},{"issue":"4","key":"pmed.1003348.ref014","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/EDE.0b013e31821c680c","article-title":"Direct and Indirect Effects in a Survival Context.","volume":"22","author":"T Lange","year":"2011","journal-title":"Epidemiology"},{"key":"pmed.1003348.ref015","first-page":"1","volume-title":"A model for non-parametric regression analysis of counting processes","author":"O. Aalen","year":"1980"},{"issue":"14","key":"pmed.1003348.ref016","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up","volume":"305","author":"GM Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"pmed.1003348.ref017","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"B Ungar","year":"2014","journal-title":"Gut"},{"issue":"1","key":"pmed.1003348.ref018","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1212\/01.wnl.0000171748.48188.5b","article-title":"Interferon -1a in MS: Results following development of neutralizing antibodies in PRISMS","volume":"65","author":"for the PRISMS (Prevention of Relapses and Disability by Interferon ss-1a Subcutaneously in Multiple Sclerosis) Study Group","year":"2005","journal-title":"Neurology"},{"issue":"12","key":"pmed.1003348.ref019","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"S Garc\u00eas","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pmed.1003348.ref020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.","volume":"53","author":"M Jani","year":"2014","journal-title":"Rheumatology"},{"issue":"10","key":"pmed.1003348.ref021","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2018-213403","article-title":"Methotrexate and BAFF interaction prevents immunization against TNF inhibitors","volume":"77","author":"S Bitoun","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"pmed.1003348.ref022","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3389\/fimmu.2018.01764","article-title":"Azithromycin Clears Bordetella pertussis Infection in Mice but Also Modulates Innate and Adaptive Immune Responses and T Cell Memory.","volume":"9","author":"L Borkner","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"pmed.1003348.ref023","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.immuni.2014.08.009","article-title":"TLR5-Mediated Sensing of Gut Microbiota Is Necessary for Antibody Responses to Seasonal Influenza Vaccination","volume":"41","author":"JZ Oh","year":"2014","journal-title":"Immunity"},{"issue":"6","key":"pmed.1003348.ref024","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cell.2019.08.010","article-title":"Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans","volume":"178","author":"T Hagan","year":"2019","journal-title":"Cell"},{"issue":"6371","key":"pmed.1003348.ref025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"B Routy","year":"2018","journal-title":"Science"},{"issue":"5","key":"pmed.1003348.ref026","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.cell.2017.01.022","article-title":"Mining the Human Gut Microbiota for Immunomodulatory Organisms","volume":"168","author":"N Geva-Zatorsky","year":"2017","journal-title":"Cell"},{"issue":"2","key":"pmed.1003348.ref027","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.immuni.2019.06.002","article-title":"Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8+ T Cells.","volume":"51","author":"A Bachem","year":"2019","journal-title":"Immunity"},{"issue":"12","key":"pmed.1003348.ref028","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2013-203485","article-title":"Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis","volume":"72","author":"P Emery","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pmed.1003348.ref029","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/art.21830","article-title":"British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register","volume":"54","author":"KL Hyrich","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"pmed.1003348.ref030","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1352458513498635","article-title":"Smoking and risk of treatment-induced neutralizing antibodies to interferon \u03b2-1a.","volume":"20","author":"AK Hedstr\u00f6m","year":"2014","journal-title":"Mult Scler J."},{"issue":"8","key":"pmed.1003348.ref031","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/1352458513515086","article-title":"Smokers run increased risk of developing anti-natalizumab antibodies.","volume":"20","author":"A Hedstr\u00f6m","year":"2014","journal-title":"Mult Scler J"},{"issue":"6","key":"pmed.1003348.ref032","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.semarthrit.2018.10.006","article-title":"Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis","volume":"48","author":"J Quistrebert","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"pmed.1003348.ref033","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1089\/jir.2016.0054","article-title":"on behalf of the ABIRISK consortium. Serum cotinine does not predict neutralizing antibodies against Interferon-beta in an Austrian MS-cohort","volume":"36","author":"M Auer","year":"2016","journal-title":"J Interferon Cytokine Res"},{"issue":"11","key":"pmed.1003348.ref034","doi-asserted-by":"crossref","first-page":"e0162752","DOI":"10.1371\/journal.pone.0162752","article-title":"Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.","volume":"11","author":"D Bachelet","year":"2016","journal-title":"PLoS ONE."},{"key":"pmed.1003348.ref035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cytogfr.2018.10.004","article-title":"Pathological roles of the homeostatic chemokine CXCL12","volume":"44","author":"R Janssens","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"pmed.1003348.ref036","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.immuni.2013.08.038","article-title":"Germinal Center Centroblasts Transition to a Centrocyte Phenotype According to a Timed Program and Depend on the Dark Zone for Effective Selection","volume":"39","author":"O Bannard","year":"2013","journal-title":"Immunity"},{"issue":"9","key":"pmed.1003348.ref037","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1073\/pnas.1611958114","article-title":"Essential role of immobilized chemokine CXCL12 in the regulation of the humoral immune response","volume":"114","author":"A Barinov","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"pmed.1003348.ref038","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1074-7613(00)80046-1","article-title":"The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment","volume":"10","author":"Q Ma","year":"1999","journal-title":"Immunity"},{"key":"pmed.1003348.ref039","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ejhg.2012.278","article-title":"Genomic correlates of variability in immune response to an oral cholera vaccine","volume":"21","author":"PP Majumder","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"pmed.1003348.ref040","doi-asserted-by":"crossref","first-page":"e0160970","DOI":"10.1371\/journal.pone.0160970","article-title":"Whole Transcriptome Profiling Identifies CD93 and Other Plasma Cell Survival Factor Genes Associated with Measles-Specific Antibody Response after Vaccination","volume":"11","author":"IH Haralambieva","year":"2016","journal-title":"PLoS ONE"},{"key":"pmed.1003348.ref041","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cellimm.2016.01.005","article-title":"Strategies to target long-lived plasma cells for treating hemophilia A inhibitors","volume":"301","author":"CL Liu","year":"2016","journal-title":"Cell Immunol"},{"issue":"1","key":"pmed.1003348.ref042","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn\u2019s Disease","volume":"158","author":"A Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"pmed.1003348.ref043","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1352458518763089","article-title":"Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials","volume":"25","author":"D Buck","year":"2019","journal-title":"Mult Scler J"},{"issue":"4","key":"pmed.1003348.ref044","doi-asserted-by":"crossref","first-page":"e0195325","DOI":"10.1371\/journal.pone.0195325","article-title":"Identification of HLA-DRB1 association to adalimumab immunogenicity.","volume":"13","author":"M Liu","year":"2018","journal-title":"PLoS ONE."},{"issue":"1","key":"pmed.1003348.ref045","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/s41467-018-04732-5","article-title":"DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.","volume":"9","author":"L Kular","year":"2018","journal-title":"Nat Commun."},{"issue":"8","key":"pmed.1003348.ref046","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1534\/g3.117.043828","article-title":"Unique Allelic eQTL Clusters in Human MHC Haplotypes.","volume":"7","author":"TH Lam","year":"2017","journal-title":"G3amp58 GenesGenomesGenetics"},{"issue":"1","key":"pmed.1003348.ref047","doi-asserted-by":"crossref","first-page":"e29819","DOI":"10.1371\/journal.pone.0029819","article-title":"Multiple Sclerosis Risk Variant HLA-DRB1*1501 Associates with High Expression of DRB1 Gene in Different Human Populations","volume":"7","author":"A Alcina","year":"2012","journal-title":"PLoS ONE."},{"key":"pmed.1003348.ref048","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jpba.2015.12.040","article-title":"Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies","volume":"120","author":"PA van Schouwenburg","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"pmed.1003348.ref049","unstructured":"EMA. Guideline on Immunogenicity assessment of therapeutic proteins, Committee for Medicinal Products for Human Use (CHMP). EMEA\/CHMP\/BMWP\/14327\/2006 Rev 1 [Internet]. 2017 [cited 2017 Jan 17]. Available from: https:\/\/www.ema.europa.eu\/en\/immunogenicity-assessment-biotechnology-derived-therapeutic-proteins#document-history\u2014revision-1-(current-version)-section"},{"key":"pmed.1003348.ref050","unstructured":"FDA. Immunogenicity Testing of Therapeutic Protein Products\u2013Developing and Validating Assays for Anti-Drug Antibody Detection. Guidance for Industry [Internet]. 2019 [cited 2019 Jan 1]. Available from: https:\/\/www.fda.gov\/regulatory-information"},{"issue":"9","key":"pmed.1003348.ref051","doi-asserted-by":"crossref","first-page":"e0162316","DOI":"10.1371\/journal.pone.0162316","article-title":"Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study.","volume":"11","author":"GP Eng","year":"2016","journal-title":"PLoS ONE."},{"issue":"5","key":"pmed.1003348.ref052","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of Anti-TNF Treatment Failure in Anti-TNF-Naive Patients with Active Luminal Crohn\u2019s Disease: A Prospective, Multicentre, Cohort Study.","volume":"4","author":"NA Kennedy","year":"2019","journal-title":"The Lancet. Gastroenterology & Hepatology"},{"issue":"3","key":"pmed.1003348.ref053","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.","volume":"9","author":"PA van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol."},{"issue":"6","key":"pmed.1003348.ref054","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","article-title":"Low immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"76","author":"GR Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pmed.1003348.ref055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/BTT.S97234","article-title":"Correlations between immunogenicity, drug levels,and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab.","volume":"10","author":"M Benucci","year":"2016","journal-title":"Biol Targets Ther."},{"issue":"1","key":"pmed.1003348.ref056","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jbspin.2016.04.013","article-title":"Immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"84","author":"J Sigaux","year":"2017","journal-title":"Joint Bone Spine"},{"issue":"12","key":"pmed.1003348.ref057","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s10067-017-3848-6","article-title":"Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.","volume":"36","author":"JT Einarsson","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"4","key":"pmed.1003348.ref058","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.","volume":"31","author":"V Strand","year":"2017","journal-title":"BioDrugs."},{"issue":"2","key":"pmed.1003348.ref059","doi-asserted-by":"crossref","first-page":"e0170395","DOI":"10.1371\/journal.pone.0170395","article-title":"Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.","volume":"12","author":"J Link","year":"2017","journal-title":"PLoS ONE."}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T13:24:50Z","timestamp":1604064290000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003348"}},"subtitle":[],"editor":[{"given":"Sebastien","family":"Viatte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003348","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]}}}